KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q3 2025 value amounting to $197.2 million.

  • Alnylam Pharmaceuticals' Cost of Revenue rose 14058.43% to $197.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $512.1 million, marking a year-over-year increase of 8564.89%. This contributed to the annual value of $306.5 million for FY2024, which is 1427.84% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Cost of Revenue is $197.2 million, which was up 14058.43% from $142.0 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Cost of Revenue high stood at $197.2 million for Q3 2025, and its period low was $23.0 million during Q1 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Cost of Revenue averaged around $65.2 million, with its median value being $54.6 million (2024).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Cost of Revenue plummeted by 1070.54% in 2024 and then soared by 14058.43% in 2025.
  • Alnylam Pharmaceuticals' Cost of Revenue (Quarter) stood at $33.6 million in 2021, then surged by 37.27% to $46.2 million in 2022, then skyrocketed by 55.88% to $72.0 million in 2023, then surged by 42.62% to $102.6 million in 2024, then soared by 92.14% to $197.2 million in 2025.
  • Its Cost of Revenue was $197.2 million in Q3 2025, compared to $142.0 million in Q2 2025 and $70.2 million in Q1 2025.